Target intelligence / Profile preview

Cullin-4-RING E3 ubiquitin ligase (CRL4)

Target
CRL4
Molecular classification
Enzyme, E3 ubiquitin ligase, Multiprotein complex
01

Overview

The Cullin-4-RING E3 ubiquitin ligase (CRL4) is a multi-subunit protein complex that plays a pivotal role in the ubiquitin-proteasome system by targeting specific substrates for degradation. The core complex is composed of a Cullin-4 scaffold (either CUL4A or CUL4B), the RING-finger protein RBX1 (also known as ROC1), and the adaptor protein DDB1, which recruits a variety of DDB1- and CUL4-associated factors (DCAFs) to act as substrate receptors. CRL4 regulates critical cellular processes, including DNA replication licensing (by degrading CDT1), nucleotide excision repair, cell cycle progression, and chromatin remodeling. Dysregulation or overexpression of CUL4 is implicated in various malignancies, such as lung, breast, and ovarian cancers, where it promotes tumor progression and metastasis, while mutations in CUL4B are linked to X-linked intellectual disability. CRL4 has emerged as a highly attractive therapeutic target, particularly through the use of molecular glues like immunomodulatory drugs (IMiDs; e.g., thalidomide, lenalidomide) and sulfonamides (e.g., indisulam), which hijack CRL4 substrate receptors (CRBN and DCAF15, respectively) to induce the degradation of neo-substrates. Additionally, direct small-molecule inhibitors of the CRL4 catalytic core (such as KH-4-43 and PA-1) are under development to block its activity and induce apoptosis in cancer cells.

Other names
Cullin-4-RING ligaseCRL4 complexCUL4-RING E3 ubiquitin ligaseCUL4-DDB1-RBX1 complexCullin-4-RING ubiquitin ligase
02

Mechanism of action

E3 ubiquitin ligase modulation, targeted protein degradation, E3 ubiquitin ligase inhibition, and molecular glue recruitment

03

Biological functions

UbiquitinationCell cycleDNA replicationDNA repairApoptosisChromatin remodelingProtein degradation
04

Disease associations

CancerX-linked intellectual disabilityInfectionHereditary spastic paraplegia
05

Safety considerations

TeratogenicityMyelosuppressionThrombosisPeripheral neuropathyOff-target protein degradationGeneral toxicity due to cell cycle arrest
06

Interacting drugs

11 more in the full profile.

07

Biomarkers

CUL4A expressionCUL4B expressionCDT1 accumulationRBM39 expressionIKZF1/IKZF3 expressionp21 expression

Beyond the preview

Go deeper on Cullin-4-RING E3 ubiquitin ligase (CRL4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cullin-4-RING E3 ubiquitin ligase (CRL4).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call